|
Canada-0-LABORATORIES 公司名錄
|
公司新聞:
- Dupilumab treatment for allergic bronchopulmonary aspergillosis: A case . . .
Thus, dupilumab appears to have a role in facilitating disease control in ABPA, with reduced symptoms and OCS use However, there may be potential for worsening of hypereosinophilia
- Treatment of allergic bronchopulmonary aspergillosis - UpToDate
The treatment and prognosis of ABPA will be reviewed here The clinical manifestations and diagnosis of ABPA and general issues related to the management of asthma and bronchiectasis are discussed separately
- Dupilumab for Aspergilloma and ABPA - American Academy of Allergy . . .
Ramonell et al published a case series of three patients with ABPA who were treated over six months Dupilumab administration was associated with improved FEV1, reduced symptoms and reduced oral corticosteroid use However, two of the three patients developed worsening hypereosinophilia
- Is Dupixent (dupilumab) useful for Allergic Bronchopulmonary . . .
Dupixent (dupilumab) is a useful treatment option for allergic bronchopulmonary aspergillosis (ABPA), particularly in patients with treatment-dependent ABPA, due to its mechanism of action in blocking interleukin-4 and interleukin-13 signaling, key drivers of type 2 inflammation involved in ABPA
- American Journal of Respiratory and Critical Care Medicine
Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukins (IL)-4 and IL-13, key and central drivers of type 2 inflammation in multiple diseases The phase 2 LIBERTY ABPA AIRED (NCT04442269) study evaluated the efficacy of dupilumab in patients with ABPA
- DUPILUMAB IN THE TREATMENT OF REFRACTORY ALLERGIC . . . - CHEST
Here, we present a case of refractory ABPA in a setting of refractory asthma with response to dupilumab
- Paradoxical effects of dupilumab in allergic bronchopulmonary . . .
Case reports have reported the efficacy of mepolizumab 5 and dupilumab 6 for ABPA, and of switching between them We report a case in which dupilumab resolved mucus plugs in ABPA but induced eosinophilic pneumonia, successfully treated with mepolizumab
- Dupilumab treatment for allergic bronchopulmonary aspergillosis: A case . . .
Thus, dupilumab appears to have a role in facilitating disease control in ABPA, with reduced symptoms and OCS use However, there may be potential for worsening of hypereosinophilia
- Successful treatment with dupilumab in mepolizumab-resistant allergic . . .
We described a patient with refractory asthma accompanied by ABPA who experienced recurrence despite receiving mepolizumab treatment, but exhibited a favorable response to dupilumab
|
|